naltrexone and Depression

naltrexone has been researched along with Depression in 54 studies

Research

Studies (54)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (3.70)	18.7374
1990's	3 (5.56)	18.2507
2000's	18 (33.33)	29.6817
2010's	27 (50.00)	24.3611
2020's	4 (7.41)	2.80

Authors

Authors	Studies
Choo, TH; Fishman, M; Lee, JD; Nunes, E; Pavlicova, M; Rotrosen, J; Vest, N; Wenzel, K	1
Burke, NN; Deaver, DR; Eyerman, DJ; Finn, DP; Kelly, JP; Li, Y; Roche, M; Sanchez, C	1
Browne, CA; Lucki, I; Smith, T	1
Chen, J; Dombrovski, AY; Karim, HT; Karp, JF; Lyew, T; Mizuno, A; Peciña, M	1
Anderson, PM; Hillhouse, TM; Kegen, TN; Koppenhaver, PO; Lane, JT; Manicka, SG; Porter, JH; Pottanat, E; Rice, R; Van Fossen, M; Zhang, F	1
Bidlack, JM; Callaghan, CK; Dean, RL; Deaver, DR; Knapp, BI; O'Mara, SM; Rouine, J	1
da Luz, SC; Nogueira, CW; Pesarico, AP; Rosa, SG; Tagliapietra, CF	1
Carroll, KM; DeVito, EE; Frankforter, TL; Kiluk, BD; Nich, C; Sofuoglu, M; Yip, SW	1
Cioe, PA; Kahler, CW; Lechner, WV; Sidhu, NK	1
Hashimoto, K; Zhang, K	1
Burke, NN; Deaver, DR; Ferdousi, M; Finn, DP; Kelly, JP; Roche, M	1
Krajci, P; Kunoe, N; Latif, ZE; Opheim, A; Šaltyte Benth, J; Sharma-Haase, K; Solli, KK; Tanum, L	1
Krystal, JH; Petrakis, IL; Yoon, G	1
Bentzley, BS; Heifets, BD; Schatzberg, AF; Williams, NR	1
Abdollahzadeh Estakhri, MR; Dehpour, AR; Haj-Mirzaian, A; Hamzeh, N; Javadi-Paydar, M	1
Banks, ML; Bowers, MS; Carlezon, WA; Cheng, K; Leitl, MD; Negus, SS; Onvani, S; Rice, KC	1
Dehpour, AR; Ejtemaei Mehr, S; Haj-Mirzaian, A; Kordjazy, N; Ostadhadi, S	1
Falcon, E; Hill-Smith, TE; Lucki, I; Maier, K; Robinson, SA	1
Booij, J; de Bruin, K; Goudriaan, AE; Koeter, MW; Lammers, LA; van den Brink, W; van Dijk, L; Zaaijer, ER	1
Almatroudi, A; Bailey, CP; Bailey, SJ; Husbands, SM	1
Adamson, SJ; Boden, JM; Foulds, JA; Mulder, RT; Newton-Howes, G; Sellman, JD	1
Ficek, J; Golda, S; Korostynski, M; Piechota, M; Przewlocki, R; Szklarczyk, K	1
Blokhina, E; Burakov, A; Bushara, N; Krupitsky, E; Masalov, D; Palatkin, V; Pecoraro, A; Romanova, T; Tsoy-Podosenin, M; Tyurina, A; Verbitskaya, E; Wahlgren, V; Woody, G; Yaroslavtseva, T; Zvartau, E	1
Epstein, A; King, A; Munisamy, G; Walsh, Z	1
Cooney, JL; Cooney, NL; McKee, SA; O'Malley, SS; Toll, BA	1
Bucello, S; Cavarretta, R; Comi, G; Cursi, M; Franchi, S; Gironi, M; Martinelli, V; Martinelli-Boneschi, F; Martino, G; Moiola, L; Nemni, R; Pilato, V; Radaelli, M; Rodegher, M; Sacerdote, P; Solaro, C; Zaffaroni, M	1
Meyer, F	1
Gopalakrishnan, R; O'Brien, C; Oslin, D; Ross, J	1
Gossop, M; Hegstad, S; Hjerkinn, B; Kristensen, Ø; Kunøe, N; Lobmaier, P; Vederhus, JK; Waal, H	1
Cheng, WY; Mysels, DJ; Nunes, EV; Sullivan, MA	1
Fujii, H; Nagase, H; Nemoto, T; Oka, J; Saitoh, A; Sugiyama, A; Wada, K; Yamada, M	1
Carlezon, WA; Chartoff, E; Pliakas, A; Potter, D; Rachlin, A; Sawyer, A	1
Jovanović, T; Lazarević, D; Nikolić, G	1
Chen, Q; Lv, SY; Qin, YJ; Wang, HT; Xu, N; Yang, YJ	1
Bailey, SJ; Casal-Dominguez, JJ; Clark, M; Husbands, SM; Traynor, JR	1
Chen, J; Duman, RS; Nestler, EJ; Neve, R; Newton, SS; Sakai, N; Schlesinger, L; Shirayama, Y; Thome, J; Wallace, TL	1
Helwig, H; Jahn, H; Kiefer, F; Otte, C; Tarnaske, T; Wiedemann, K	1
Connor, JP; Dean, AJ; Jones, RT; Lawford, BR; Saunders, JB; Young, RM	1
Deas, D; Dosh, T; Kazura, A; Kratochvil, CJ; Martin, CA; Wilens, TE	1
Roesner, S; Soyka, M	1
Capone, C; Farren, CK; Grilo, CM; McKee, SA; O'Malley, SS; Rounsaville, BJ; Sinha, R; Wu, R	1
al'Absi, M; Bruehl, S; Burns, JW; Chung, OY; France, CR; France, J; Harju, A	1
Drummond, PD; Frew, AK	1
Bohus, B; Cottrell, GA; Nyakas, C	1
Goldberg, G; Mantero-Atienza, E; Mason, BJ; Morgan, RO; Ritvo, EC; Salvato, FR; Welch, B	1
Swift, RM	1
Albano, SA; Wiley, DB; Zaim, S	1
Befort, K; Chluba, J; Dierich, A; Filliol, D; Gavériaux-Ruff, C; Ghozland, S; Kieffer, BL; LeMeur, M; Maldonado, R; Martin, M; Matthes, HW; Simonin, F; Valverde, O	1
Brandão, ML; Cuadra, G; Martijena, I; Molina, V; Zurita, A	1
Bolm, T; Piegler, T	1
Kranzler, HR; Van Kirk, J	1
Basch, J; Ling, W; McCann, M; Miotto, K; Rawson, R	1
Lewis, DC	1

Reviews

4 review(s) available for naltrexone and Depression

Article	Year
New pharmacological approaches for the treatment of alcoholism. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:17 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Animals; Carbamazepine; Depression; Disease Models, Animal; Disulfiram; Fructose; Humans; Naltrexone; Secondary Prevention; Taurine; Topiramate	2006
The pharmacological treatment of alcohol dependence. Medicine and health, Rhode Island, 1997, Volume: 80, Issue:3 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Antidepressive Agents; Comorbidity; Depression; Disulfiram; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Serotonin Antagonists; Serotonin Receptor Agonists; Taurine	1997
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:9 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome	2001
Naltrexone and dysphoria: fact or myth? The American journal on addictions, 2002,Spring, Volume: 11, Issue:2 Topics: Affect; Depression; Humans; Naltrexone; Narcotic Antagonists; Substance-Related Disorders	2002

Trials

16 trial(s) available for naltrexone and Depression

Article	Year
Naltrexone modulates contextual processing in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2020, Volume: 45, Issue:12 Topics: Cross-Over Studies; Depression; Double-Blind Method; Emotions; Facial Expression; Humans; Magnetic Resonance Imaging; Naltrexone	2020
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug and alcohol dependence, 2018, 11-01, Volume: 192 Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Depression; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Patient Dropouts; Treatment Outcome	2018
Effects of time-varying changes in tobacco and alcohol use on depressive symptoms following pharmaco-behavioral treatment for smoking and heavy drinking. Drug and alcohol dependence, 2019, 01-01, Volume: 194 Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Behavior Therapy; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Smoking Cessation; Time Factors; Tobacco Smoking; Tobacco Use Disorder	2019
Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study. JAMA psychiatry, 2019, 02-01, Volume: 76, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Anxiety; Buprenorphine, Naloxone Drug Combination; Comorbidity; Delayed-Action Preparations; Depression; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Male; Middle Aged; Naltrexone; Opioid-Related Disorders; Sleep Initiation and Maintenance Disorders; Young Adult	2019
Personality Predictors of Drinking Outcomes in Depressed Alcohol-Dependent Patients. Alcohol and alcoholism (Oxford, Oxfordshire), 2016, Volume: 51, Issue:3 Topics: Adult; Alcoholism; Character; Citalopram; Depression; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Personality Inventory; Prognosis; Temperament; Treatment Outcome; Young Adult	2016
Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant. The American journal of drug and alcohol abuse, 2016, Volume: 42, Issue:5 Topics: Administration, Oral; Adult; Anhedonia; Anxiety; Craving; Delayed-Action Preparations; Depression; Double-Blind Method; Drug Implants; Female; Humans; Male; Naltrexone; Opioid-Related Disorders; Treatment Outcome; Young Adult	2016
The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. Journal of addictive diseases, 2008, Volume: 27, Issue:1 Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Counseling; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Personality Inventory; Smoking Cessation; Treatment Outcome	2008
Course of late-life depression with alcoholism following combination therapy. Journal of studies on alcohol and drugs, 2009, Volume: 70, Issue:2 Topics: Aging; Alcoholism; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Diagnosis, Dual (Psychiatry); Female; Humans; Male; Middle Aged; Naltrexone; Placebos; Sertraline; Severity of Illness Index; Treatment Outcome	2009
Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction (Abingdon, England), 2010, Volume: 105, Issue:9 Topics: Adult; Crime; Delayed-Action Preparations; Depression; Drug Implants; Drug Overdose; Euphoria; Female; Hair; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Narcotics; Opioid-Related Disorders; Patient Compliance; Psychiatric Status Rating Scales; Secondary Prevention; Substance Abuse Detection; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult	2010
The association between naltrexone treatment and symptoms of depression in opioid-dependent patients. The American journal of drug and alcohol abuse, 2011, Volume: 37, Issue:1 Topics: Adult; Affect; Depression; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Opioid-Related Disorders; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome	2011
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. European addiction research, 2005, Volume: 11, Issue:2 Topics: Acamprosate; Adolescent; Adult; Aged; Alcohol Deterrents; Alcoholism; Anxiety Disorders; Depression; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Narcotics; Predictive Value of Tests; Prospective Studies; Secondary Prevention; Somatoform Disorders; Surveys and Questionnaires; Taurine; Treatment Outcome	2005
Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence. Journal of psychiatry & neuroscience : JPN, 2006, Volume: 31, Issue:1 Topics: Adult; Depression; Female; Heroin Dependence; Humans; Male; Methadone; Naltrexone; Narcotic Antagonists	2006
Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial. Alcoholism, clinical and experimental research, 2007, Volume: 31, Issue:4 Topics: Adaptation, Psychological; Adult; Alcohol Drinking; Alcoholism; Attitude; Body Mass Index; Bulimia; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Feeding and Eating Disorders; Female; gamma-Glutamyltransferase; Humans; Naltrexone; Narcotic Antagonists; Psychiatric Status Rating Scales; Treatment Outcome	2007
Anger management style and endogenous opioid function: is gender a moderator? Journal of behavioral medicine, 2007, Volume: 30, Issue:3 Topics: Adult; Anger; Anxiety; Depression; Double-Blind Method; Electric Stimulation; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Nociceptors; Opioid Peptides; Pain Threshold; Sex Factors; Skin; Statistics as Topic	2007
A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcoholism, clinical and experimental research, 1994, Volume: 18, Issue:5 Topics: Alcoholism; Body Weight; Depression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Humans; Naltrexone; Narcotic Antagonists; Patient Admission; Pilot Projects; Treatment Outcome	1994
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism, clinical and experimental research, 2001, Volume: 25, Issue:9 Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Depression; Female; gamma-Glutamyltransferase; Humans; Male; Naltrexone; Narcotic Antagonists; Placebos; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Taurine; Treatment Outcome	2001

Other Studies

35 other study(ies) available for naltrexone and Depression

Article	Year
Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial. The American journal on addictions, 2023, Volume: 32, Issue:3 Topics: Adult; Analgesics, Opioid; Buprenorphine; Depression; Humans; Naltrexone; Opioid-Related Disorders	2023
Chronic administration of buprenorphine in combination with samidorphan produces sustained effects in olfactory bulbectomised rats and Wistar-Kyoto rats. Journal of psychopharmacology (Oxford, England), 2019, Volume: 33, Issue:12 Topics: Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Locomotion; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley	2019
Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression. European journal of pharmacology, 2020, Apr-05, Volume: 872 Topics: Animals; Behavior Observation Techniques; Behavior, Animal; Depression; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Repositioning; Female; Humans; Male; Mice; Mice, Knockout; Naltrexone; Nucleus Accumbens; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Factors	2020
Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice. Pharmacology, biochemistry, and behavior, 2021, Volume: 208 Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Depression; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Female; Hindlimb Suspension; Ketamine; Locomotion; Male; Mice; Mice, Inbred C57BL; Naltrexone; Narcotic Antagonists; Psychomotor Agitation; Receptors, Opioid	2021
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model. Brain, behavior, and immunity, 2018, Volume: 67 Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Brain-Derived Neurotrophic Factor; Cell Proliferation; Depression; Depressive Disorder; Disease Models, Animal; Hippocampus; Interferon-alpha; Male; Naltrexone; Narcotic Antagonists; Neurons; Rats, Wistar; Receptors, Opioid	2018
Opioid system contribution to the antidepressant-like action of m-trifluoromethyl-diphenyl diselenide in mice: A compound devoid of tolerance and withdrawal syndrome. Journal of psychopharmacology (Oxford, England), 2017, Volume: 31, Issue:9 Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder; Male; Mice; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Organosilicon Compounds; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Swimming	2017
Lack of Opioid System in the Antidepressant Actions of Ketamine. Biological psychiatry, 2019, 03-15, Volume: 85, Issue:6 Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Ketamine; Lipopolysaccharides; Male; Mice; Naltrexone; Stress, Psychological	2019
Locomotor and anti-immobility effects of buprenorphine in combination with the opioid receptor modulator samidorphan in rats. Neuropharmacology, 2019, 03-01, Volume: 146 Topics: Amygdala; Animals; Behavior, Animal; Buprenorphine; Depression; Hippocampus; Male; Motor Activity; Naltrexone; Nociceptin; Opioid Peptides; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Receptors, Opioid, mu; RNA, Messenger; Swimming	2019
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect-Reply. JAMA psychiatry, 2019, 06-01, Volume: 76, Issue:6 Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid	2019
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. JAMA psychiatry, 2019, 06-01, Volume: 76, Issue:6 Topics: Alcoholism; Antidepressive Agents; Depression; Humans; Ketamine; Naltrexone; Receptors, Opioid	2019
Resistance to depression through interference of opioid and nitrergic systems in bile-duct ligated mice. European journal of pharmacology, 2013, May-15, Volume: 708, Issue:1-3 Topics: Animals; Bile Ducts; Cholestasis; Depression; Enzyme Inhibitors; Ligation; Male; Mice; Motor Activity; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Swimming	2013
Pain-related depression of the mesolimbic dopamine system in rats: expression, blockade by analgesics, and role of endogenous κ-opioids. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:3 Topics: Analgesics, Opioid; Animals; Benzeneacetamides; Depression; Disease Models, Animal; Dopamine; Gene Expression Regulation; Ketoprofen; Lactic Acid; Male; Medial Forebrain Bundle; Morphine; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Pain; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Self Stimulation; Time Factors	2014
Opioid/NMDA receptors blockade reverses the depressant-like behavior of foot shock stress in the mouse forced swimming test. European journal of pharmacology, 2014, Jul-15, Volume: 735 Topics: Analgesics, Opioid; Animals; Behavior, Animal; Depression; Dizocilpine Maleate; Electroshock; Foot; Male; Mice; Morphine; Motor Activity; N-Methylaspartate; Naltrexone; Narcotic Antagonists; Receptors, N-Methyl-D-Aspartate; Receptors, Opioid; Stress, Psychological; Swimming	2014
Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology, 2015, Volume: 232, Issue:5 Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Behavior, Animal; Buprenorphine; Depression; Desipramine; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Activity; Naltrexone; Narcotics; Nucleus Accumbens; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Swimming	2015
Effect of extended-release naltrexone on striatal dopamine transporter availability, depression and anhedonia in heroin-dependent patients. Psychopharmacology, 2015, Volume: 232, Issue:14 Topics: Adult; Anhedonia; Corpus Striatum; Delayed-Action Preparations; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Plasma Membrane Transport Proteins; Female; Heroin Dependence; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Positron-Emission Tomography; Psychiatric Status Rating Scales; Radiopharmaceuticals; Substance Abuse Detection; Tomography, Emission-Computed, Single-Photon; Tropanes	2015
Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:7 Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Buprenorphine; Depression; Disease Models, Animal; Drug Therapy, Combination; Male; Maze Learning; Mice; Naltrexone; Narcotic Antagonists; Receptors, Opioid, kappa; Receptors, Opioid, mu	2015
Endogenous opioids regulate glucocorticoid-dependent stress-coping strategies in mice. Neuroscience, 2016, 08-25, Volume: 330 Topics: Adaptation, Psychological; Amygdala; Animals; Anxiety; Conditioning, Psychological; Depression; Dexamethasone; Fear; Freezing Reaction, Cataleptic; Glucocorticoids; Male; Mice, Inbred Strains; Mifepristone; Motor Activity; Naltrexone; Neurotransmitter Agents; Opioid Peptides; Receptors, Glucocorticoid; Receptors, Opioid; Species Specificity; Stress, Psychological	2016
Correspondence of Interactive Voice Response (IVR) reports of nicotine withdrawal, craving, and negative mood with questionnaire ratings. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco, 2008, Volume: 10, Issue:6 Topics: Adult; Comorbidity; Depression; Female; Humans; Irritable Mood; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nicotine; Self Disclosure; Self-Assessment; Smoking Cessation; Substance Withdrawal Syndrome; Surveys and Questionnaires	2008
A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England), 2008, Volume: 14, Issue:8 Topics: Adolescent; Adult; Aged; Depression; Disabled Persons; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Receptors, Opioid, mu; RNA, Messenger	2008
Alleviation of both binge eating and sexual dysfunction with naltrexone. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:6 Topics: Alcoholism; Antidepressive Agents; Bulimia; Child; Child Abuse; Depression; Female; Heroin Dependence; Humans; Middle Aged; Naltrexone; Narcotic Antagonists; Selective Serotonin Reuptake Inhibitors; Sex Work; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Stress Disorders, Post-Traumatic	2008
Treating depression along with alcohol dependence. The Harvard mental health letter, 2010, Volume: 27, Issue:1 Topics: Alcohol-Related Disorders; Depression; Health Knowledge, Attitudes, Practice; Humans; Naltrexone; Narcotic Antagonists; Randomized Controlled Trials as Topic	2010
The novel δ opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions. Behavioural brain research, 2011, Oct-01, Volume: 223, Issue:2 Topics: Analgesics; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Benzamides; Depression; Dopamine Antagonists; Imipramine; Male; Mice; Mice, Inbred ICR; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Pain Measurement; Piperazines; Receptors, Opioid, delta; Seizures; Swimming	2011
Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology, 2012, Volume: 62, Issue:1 Topics: Analysis of Variance; Animals; Cocaine; Conditioning, Operant; Depression; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Administration Routes; Immobility Response, Tonic; Male; Naltrexone; Narcotic Antagonists; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, Opioid, kappa; Reinforcement Schedule; Self Administration; Substance Withdrawal Syndrome; Swimming; Time Factors	2012
[Differences in depression severity and frequency of relapses in opiate addicts treated with methadone or opiate blocker after detoxification]. Vojnosanitetski pregled, 2012, Volume: 69, Issue:4 Topics: Adult; Depression; Humans; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Recurrence; Young Adult	2012
Centrally administered apelin-13 induces depression-like behavior in mice. Brain research bulletin, 2012, Sep-01, Volume: 88, Issue:6 Topics: Amino Acid Sequence; Animals; Apelin Receptors; Corticotropin-Releasing Hormone; Depression; Injections; Injections, Intraventricular; Intercellular Signaling Peptides and Proteins; Male; Mice; Motor Activity; Naloxone; Naltrexone; Peptide Fragments; Receptor, Angiotensin, Type 1; Receptors, Corticotropin-Releasing Hormone; Receptors, G-Protein-Coupled; Receptors, Opioid, kappa; Rotarod Performance Test; Single-Blind Method	2012
In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor. Journal of psychopharmacology (Oxford, England), 2013, Volume: 27, Issue:2 Topics: Analgesics; Animals; Anxiety; Behavior, Animal; Depression; Guinea Pigs; Ligands; Male; Mice; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar; Receptors, Opioid, kappa; Receptors, Opioid, mu	2013
Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Dec-15, Volume: 22, Issue:24 Topics: Animals; Antidepressive Agents; Behavior, Animal; Cyclic AMP Response Element-Binding Protein; Depression; Dynorphins; Enkephalins; Helplessness, Learned; Immunohistochemistry; Male; Mice; Mice, Transgenic; Mutation; Naltrexone; Nucleus Accumbens; Prosencephalon; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa	2002
Pharmacological management of a teen with significant alcohol use and depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:8 Topics: Adolescent; Alcoholism; Antidepressive Agents; Depression; Female; Humans; Naltrexone; Narcotic Antagonists; Sertraline	2006
Negative affect, pain and sex: the role of endogenous opioids. Pain, 2007, Volume: 132 Suppl 1 Topics: Adolescent; Adult; Affect; Anger; Anxiety; Central Nervous System; Cold Temperature; Depression; Double-Blind Method; Electroshock; Female; Humans; Male; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Opioid Peptides; Pain; Pain Measurement; Pain Threshold; Physical Stimulation; Sex Characteristics; Stress, Psychological	2007
The behavioural depression of hippocampal kindled rats is attenuated by subcutaneous and intracerebroventricular naltrexone. Progress in neuro-psychopharmacology & biological psychiatry, 1984, Volume: 8, Issue:4-6 Topics: Amygdala; Animals; Depression; Humans; Injections, Intraventricular; Injections, Subcutaneous; Kindling, Neurologic; Male; Naloxone; Naltrexone; Rats; Rats, Inbred Strains	1984
Rhabdomyolysis associated with naltrexone. The Annals of pharmacotherapy, 1999, Volume: 33, Issue:3 Topics: Adult; Alcoholism; Depression; Humans; Male; Naltrexone; Narcotic Antagonists; Rhabdomyolysis	1999
Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nature genetics, 2000, Volume: 25, Issue:2 Topics: Animals; Anxiety; Binding Sites; Darkness; Depression; Electroshock; Female; Gene Deletion; Light; Male; Mice; Mice, Knockout; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Pain Threshold; Phenotype; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sex Characteristics; Swimming	2000
Early exposure to chronic variable stress facilitates the occurrence of anhedonia and enhanced emotional reactions to novel stressors: reversal by naltrexone pretreatment. Behavioural brain research, 2000, Dec-20, Volume: 117, Issue:1-2 Topics: Animals; Avoidance Learning; Behavior, Animal; Chronic Disease; Conditioning, Psychological; Depression; Disease Models, Animal; Fear; Feeding Behavior; Male; Maze Learning; Naltrexone; Narcotic Antagonists; Opioid Peptides; Random Allocation; Rats; Rats, Wistar; Single-Blind Method; Stress, Psychological	2000
[Naltrexone in the treatment of dissociative disorders--reflections with regard to a comprehensive therapeutic concept of borderline disorders]. Psychiatrische Praxis, 2001, Volume: 28, Issue:5 Topics: Adult; Borderline Personality Disorder; Combined Modality Therapy; Depression; Dissociative Disorders; Female; Humans; Naltrexone; Narcotic Antagonists; Psychotherapeutic Processes; Psychotherapy; Self-Injurious Behavior; Stress Disorders, Post-Traumatic; Treatment Outcome	2001
The clinical usefulness of narcotic antagonists: preliminary findings on the use of naltrexone. The American journal of drug and alcohol abuse, 1975, Volume: 2, Issue:3-4 Topics: Adult; Alcoholism; Boston; Cannabis; Depression; Emotions; Follow-Up Studies; Heroin Dependence; Humans; Internal-External Control; Male; Naloxone; Naltrexone; Patient Acceptance of Health Care; Patient Dropouts; Psychotherapy; Self Concept; Sleep	1975